|
Banking on the growth in the chronic segment, the Indian Pharmaceutical Market (IPM) reported 6.2 per cent growth in September this year as compared to the same month last year.
Chronic segment growth for September this year has been the third highest in the last five years when compared with September month of preceding year. The chronic sector registered about 11 per cent growth in September 2022 as against 10.3 per cent growth in the same month preceding year.
On the other hand, acute segment and overall growth has been the lowest for September 2022 as compared to September 2021 in the last five years. The acute sector registered just 3.6 per cent in September this year as against 14.6 per cent growth in the same month last year. The overall growth of the domestic pharma market stood at 6.2 per cent in September 2022 as compared to 13.1 per cent in the same month previous year.
As per moving annual total (MAT), acute segment growth declined significantly to mere 5.1 per cent in September 2022 from a high of 21 per cent for September 2021.
According to MAT, chronic segment growth however has remained resilient slowing down to 9 per cent in September 2022 from a five year high of 12.8 per cent reported in September 2021. For the month of September 2022, it was higher at 11 per cent. Anti-infective, gastrointestinal, vitamins/minerals/nutrients were the top 3 therapies of acute segment in September 2022. Cardiac, antidiabetic, neuro/CNS were the top three therapies in the chronic segment. Opthal/otological, gynae and respiratory were the fastest growing therapies in the acute segment. Pain/analgesics, antineoplastic/immunomodulator and urology were the fastest growing therapies in the chronic segment.
As per MAT, in the acute segment, growth of Indian and MNC is very close. Indian companies have grown by 5.5 per cent while MNC have grown by 3.6 per cent in September this year. In the chronic segment, a big gap emerged in performance of Indian companies and MNC from 2019. Indian companies have grown by 10.3 per cent while MNC have grown by 3.6 per cent. At overall level, Indian companies grew by 7.2 per cent while MNC grew by 3.6 per cent.
September 2022 has shown a low growth over August 2022. Acute segment has shown degrowth while chronic has grown by just 1.5 per cent. As per MAT, IPM reported a reduced growth of 6.6 per cent in September 2022 as compared to 7.1 per cent growth in August 2022. Growth in the anti-infective segment has slowed down considerably as the monthly growth is just 0.5 per cent in September 2022. All the top five compositions in this therapy- amoxycillin + clavulanic acid combination, ceftriaxone, azithromycin, cefixime and cefpodoxime have witnessed either less growth or even degrowth for the month.
As per MAT September 2022, total 2545 brands were launched in the last 12 months generating an overall sale of Rs. 1,298.1 crore. New products launched in the last 12 months contributed 10.6 per cent to the MAT growth.
Manforce, Ryzodeg, Foracort, T-Bact and Electral were the top five fastest growing brands among the top 40 brands in IPM.
|